The DIM BioConvS Innovation Day 2024, taking place on November 28th at the Regional Council of Île-de-France in Saint-Ouen-sur-Seine, represents a crucial event for the future of synthetic biology and biotherapy. Organized by the DIM BioConvS (Domaine d’Intérêt Majeur Bioconvergence pour la santé), this event aims to foster interdisciplinary collaboration, bringing together researchers, companies, and innovation platforms to explore the latest advancements and opportunities in these dynamic fields.

The Innovation Day focuses on bridging the gap between synthetic biology and biotherapies, particularly those targeting the microbiome. This year’s event will showcase how innovations in synthetic biology can drive the next generation of therapeutic solutions. Attendees will have the opportunity to engage in short talks, innovation pitches, and a poster session that will highlight cutting-edge research and technologies. The event is designed to promote direct interactions between academia and industry, enabling researchers and businesses to connect and explore potential partnerships.

One of the key highlights of the day will be the “village of stands,” which will feature local companies and research platforms, providing a comprehensive view of the Île-de-France region’s scientific innovations. Participants will have the chance to engage with these exhibitors, learn about their latest developments, and explore potential collaborations. Whether attending the short talks or visiting the stands, participants can expect a day rich in information and networking.

The Paris Biofoundry’s involvement in this event underscores its ongoing commitment to advancing the field of synthetic biology and supporting the development of biotherapeutic solutions. By participating in such collaborative platforms, the biofoundry continues to play a critical role in driving the adoption of biofoundry technologies, which streamline the process of bioproduction and enhance the scalability of therapeutic applications.

At the Innovation Day, the Paris Biofoundry will contribute to discussions on how biofoundries facilitate cross-disciplinary collaboration between synthetic biologists, biotechnologists, and clinicians. As biofoundries become increasingly vital for advancing therapeutic research and industrial applications, the Biofoundry’s participation in events like this serves as a testament to its role in advancing the biotechnology ecosystem, offering invaluable insights into the development and deployment of biotechnological innovations.

This day of innovation and collaboration is an opportunity to engage with leaders in synthetic biology and biotherapies, share ideas, and form lasting partnerships. The event’s focus on microbiome-centered biotherapies and synthetic biology innovations is particularly relevant, as the microbiome is increasingly recognized for its critical role in human health. By showcasing innovations in both research and application, DIM BioConvS Innovation Day 2024 is set to be a key event in shaping the future of biotechnological research and therapeutics.

L’article Paris Biofoundry at DIM BioConvS Innovation Day 2024 est apparu en premier sur Paris Biofoundry.

The SynBioTherapy Symposium 2024, happening today November 27th, is held at the Learning Planet Institute in Paris. This event, organized by DIM BioConvS, serves as a pivotal gathering at the intersection of synthetic biology and biotherapies, exploring the transformative potential of these fields to address critical healthcare challenges.

As part of the event, Stéphane Lemaire, Director of the Paris Biofoundry, will take the stage to highlight the crucial role of biofoundries in advancing therapeutic research. His talk will delve into the innovative capabilities of biofoundries, particularly their ability to accelerate the design, testing, and production of biotherapeutic solutions. Through a combination of automation, data-driven design, and cutting-edge experimental tools, biofoundries like the Paris Biofoundry empower researchers to overcome the traditional limitations of biotech development.

This symposium will bring together prominent international experts to share insights into the latest breakthroughs in the application of synthetic biology to therapeutics. Notable speakers such as Velia Siciliano, Head of Synthetic Biology and Systems for Biomedicine at IIT Naples, and Filippo Menolascina, Director of the Engineering Biology Centre at the University of Edinburgh, will present on topics ranging from gene therapy to the engineering of mammalian cells for therapeutic use. These discussions will highlight the intersection of biotechnological advancements and real-world clinical applications, with a focus on microbiome-centered biotherapies, an emerging field with great promise for treating a range of diseases.

The event will also provide attendees with ample opportunities for networking and collaboration. Interactive sessions, roundtable discussions, and opportunities to connect with researchers from around the world will enable participants to explore the synergies between synthetic biology, biotherapy, and the broader healthcare industry.

The Paris Biofoundry, as an active player in synthetic biology, continues to foster innovation and facilitate collaboration across international research communities. Its participation in such events underlines its commitment to addressing global health challenges and advancing biotechnological solutions. By leveraging the latest advancements in automation, data science, and experimental technologies, biofoundries are poised to redefine the future of healthcare and therapeutic development.

As synthetic biology and biotherapy continue to evolve, the SynBioTherapy Symposium 2024 provides an invaluable platform for researchers, biotechnologists, and medical professionals to stay at the forefront of these dynamic fields. The event promises to be a significant milestone in driving the next wave of biotechnological innovation, ensuring that both synthetic biology and biotherapies can be applied to solve some of the world’s most pressing health issues.

L’article The Paris Biofoundry at the SynBioTherapy Symposium 2024 est apparu en premier sur Paris Biofoundry.

What is the Global Biofoundry Alliance?

The Global Biofoundry Alliance is an international network of biofoundries dedicated to advancing synthetic biology through shared resources, research, and open collaboration. Biofoundries within this network work across diverse areas such as health, industrial biotechnology, and sustainability, tackling challenges like clean energy and environmental restoration.

At this year’s summit, members will have the opportunity to present breakthroughs, discuss strategic collaborations, and explore how biofoundries can further contribute to global innovation.

Paris Biofoundry’s Role

As a state-of-the-art synthetic biology research platform based in Paris, the Paris Biofoundry plays a pivotal role in the global biofoundry ecosystem. Through its expertise in large-scale biological engineering and its focus on solving real-world problems in health, sustainability, and industry, the Paris Biofoundry is a key participant in the global conversation on biotechnology.

Looking Ahead to GBA 2024

During the GBA 2024 summit, the Paris Biofoundry team will engage in sessions on bioengineering, explore new opportunities for international collaborations, and share their latest research with peers from around the world. The summit promises to be a hub of knowledge exchange and innovation, pushing the boundaries of synthetic biology research.

The GBA 2024 Program offers a diverse array of sessions, including keynote speeches, technical workshops, and panel discussions on cutting-edge synthetic biology innovations. Today was the opening day which included a welcoming speech by Byung-Kwan Cho, director of the K-Biofoundry, followed by presentations on new biofoundry methodologies and collaborative projects. The summit also covers critical themes like sustainability, healthcare, and industrial biotech, providing a platform for networking and idea exchange.

As is it the first time the Paris Biofoundry attended the GBA summit, it will have the opportunity to introduce itself to the world as part of the keynote speeches of Friday’s program, on october 11th at 12:20 (GMT+9).

We look forward to meaningful discussions with fellow biofoundries and contributing to the future of biotechnology.

L’article The Paris Biofoundry was at the Global Biofoundry Alliance Summit 2024 est apparu en premier sur Paris Biofoundry.

We are thrilled to announce the official launch of the Paris Biofoundry, a pioneering initiative that brings together leading research institutions from across the Île-de-France region. Focused on advancing synthetic biology, the Paris Biofoundry offers state-of-the-art facilities to engineer and test biological systems at unprecedented scales. By fostering collaboration among world-class researchers, students, and industry partners, the Biofoundry is poised to develop groundbreaking innovations in health, environment, and biotechnology.

With a network of specialized sites, including platforms dedicated to DNA assembly, cell line engineering, microbial technology, and industrial scalability, the Paris Biofoundry is set to become a cornerstone of biotechnological advancement in France. The facility not only drives scientific discovery but also cultivates the next generation of synthetic biology leaders through education and hands-on research opportunities.

Here’s a closer look at the four distinct platforms that make up the Paris Biofoundry:

• The DNA and Microbe Biofoundry: The Alliance Sorbonne Université Biofoundry focuses on the assembly of DNA parts and the engineering and phenotyping of biological chassis. The ASU Biofoundry is critical for supporting all Paris Biofoundry projects by providing foundational components and expertise for synthetic biology experiments.

• The Mammalian Biofoundry: Specializing in engineering mammalian cell lines, the platform at the Institut Curie is at the forefront of medical applications, particularly for cancer research and therapeutic development. The platform supports the creation and phenotyping of cellular systems designed for clinical use.

• The Cell-free Biofoundry: This platform is dedicated to cell-free experiments and the development of software solutions to aid other Paris Biofoundry projects. The Micalis Institute enables researchers to conduct biochemical reactions outside of living cells, opening new possibilities in synthetic biology and biotechnology.

• The Industrial Biofoundry: Genopole’s platform is focused on scaling up innovations for industrial use and fostering industrial collaborations. From small-scale experiments to full-scale production, this platform ensures that the Biofoundry’s innovations can be applied in real-world industrial processes, advancing biomanufacturing and environmental solutions.

As the Paris Biofoundry embarks on this journey, we invite researchers, industry leaders, and innovators to join us in shaping the future of biotechnology. Together, we will address critical global challenges and unlock new possibilities for health and sustainability.

Explore more at parisbiofoundry.org and discover how you can be part of this exciting new chapter in synthetic biology.

L’article Introducing the Paris Biofoundry: Revolutionizing Synthetic Biology in France est apparu en premier sur Paris Biofoundry.